Following President Trump’s Executive Order on Reducing Anti-Competitive Regulatory Barriers, the FTC—led by Chairman Andrew Ferguson—launched a public inquiry this week into “how federal regulations can harm competition in...more
Exactly two weeks after issuing an interim staff report on Pharmaceutical Benefit Managers (PBMs) pursuant to its Section 6(b) authority to study markets, the Federal Trade Commission (FTC) has initiated another 6(b) study...more
Since the beginning of Chair Khan’s tenure at the Federal Trade Commission (and in line with President Biden’s aim to curb rising health care costs), the current FTC has committed to bring enforcement actions against health...more
The Federal Trade Commission (“FTC”) announced Monday that it had reversed its in-house Administrative Law Judge’s (“ALJ”) Initial Decision dismissing a complaint brought by FTC staff against Illumina, Inc.’s acquisition of...more
4/6/2023
/ Acquisition Agreements ,
Administrative Law Judge (ALJ) ,
Anti-Competitive ,
Antitrust Provisions ,
Competition ,
Divestment ,
Enforcement Actions ,
Federal Trade Commission (FTC) ,
Life Sciences ,
Merger Controls ,
Pharmaceutical Industry ,
Section 7 ,
The Clayton Act ,
Vertical Mergers